Celgene Corp (CELG)

107.22
0.91 0.86
NASDAQ : Health Care
Prev Close 106.31
Open 106.38
Day Low/High 105.69 / 107.50
52 Wk Low/High 92.98 / 137.54
Volume 1.94M
Avg Volume 4.24M
Exchange NASDAQ
Shares Outstanding 775.11M
Market Cap 84.82B
EPS 2.00
P/E Ratio 45.98
Div & Yield N.A. (N.A)

Latest News

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

The market is fearful. Use that fear to buy, Cramer says.

Allergan's Vitae Buy Could Spark More Interest in Kadmon

Allergan's Vitae Buy Could Spark More Interest in Kadmon

Hedge fund billionaire Dan Loeb owns a greater than 17% stake in the newly public developer of a drugs including those for treatment of psoriasis.

Oral Ozanimod Efficacy And Safety Results At 2 Years From Phase 2 RADIANCE Trial Of Patients With Relapsing Multiple Sclerosis Presented At 32nd ECTRIMS

Oral Ozanimod Efficacy And Safety Results At 2 Years From Phase 2 RADIANCE Trial Of Patients With Relapsing Multiple Sclerosis Presented At 32nd ECTRIMS

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from the 96-week blinded extension period (for a total of up to 120 weeks of exposure on treatment) of...

5 Healthy Pharma and Biotech Plays

5 Healthy Pharma and Biotech Plays

These stocks look good as seasonal volatility sets in.

First-Ever Psoriatic Arthritis Awareness Day Aims To Educate On Importance Of Early Diagnosis And Treatment

First-Ever Psoriatic Arthritis Awareness Day Aims To Educate On Importance Of Early Diagnosis And Treatment

Celgene Corporation (NASDAQ: CELG) and the National Psoriasis Foundation (NPF) have united to mark Wednesday, September 28 th as the first-ever Psoriatic Arthritis (PsA) Awareness Day—a day dedicated to raising public...

Celgene Announces Interim Topline Data From Trial Of Investigational Oral GED-0301 In Patients With Active Crohn's Disease

Celgene Announces Interim Topline Data From Trial Of Investigational Oral GED-0301 In Patients With Active Crohn's Disease

Celgene Corporation (NASDAQ:CELG) today announced interim topline data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects of oral GED-0301 (mongersen) on both endoscopic and...

Agios Shares Spike on Planned Drug Application

Agios Shares Spike on Planned Drug Application

The drugmaker plans to submit the first targeted-blood-cancer drug to the U.S. by the end of the year.

Agios Blood Cancer Drug Heading to Early FDA Filing by Partner Celgene

Agios Blood Cancer Drug Heading to Early FDA Filing by Partner Celgene

Celgene owns the rights to the Agios drug known as AG-221 under an existing partnership.

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.

Next Up for Celgene's Crohn's Pill: A Snapshot Inside Patients' Colons (Updated)

Next Up for Celgene's Crohn's Pill: A Snapshot Inside Patients' Colons (Updated)

GED-0301 is one of three drugs -- Otezla and ozanimod are the others -- which form the core of Celgene's burgeoning immunology and inflammation franchise.

Celgene's Deep Pullback Reaches Key Support

Celgene's Deep Pullback Reaches Key Support

For patient Celgene investors, a very low-risk buying opportunity is developing.

Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal

Medivation Proxy Shows Pfizer Battled Four Bidders to Seal a Deal

So says a proxy filing made after trading on Tuesday, as a couple of suitors included contingent value rights in their bids for the marketer of prostate cancer drug, Xtandi.

Celgene Corporation To Webcast At Upcoming Investor Conferences And R&D Deep Dive In September

Celgene Corporation To Webcast At Upcoming Investor Conferences And R&D Deep Dive In September

Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences and at an R&D deep dive in September where Celgene management will provide an overview of the Company.

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed

Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed

Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.

Gold Bug Shakeout May Be Underway

It's possible in light of VanEck Vectors Gold Miners ETF breaking down from a four-week trading range.

Medivation Scores Premium in Sale to Pfizer

Medivation Scores Premium in Sale to Pfizer

Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.

Crude Selloff, Health Care Rally Split Wall Street

Crude Selloff, Health Care Rally Split Wall Street

Stocks fluctuate on Monday as doubts over a production freeze agreement from major oil-producing countries snapped crude oil's recent rally.

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation

Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

Gilead May Be Better Off Splitting Itself in Two, Analysts Say

A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.

Olympic Swimmer And Author Dara Torres Teams Up With Celgene To Launch SHOW MORE OF YOU Psoriasis Campaign

Olympic Swimmer And Author Dara Torres Teams Up With Celgene To Launch SHOW MORE OF YOU Psoriasis Campaign

Twelve-time Olympic medalist, best-selling author, host of a cable sports TV show, and mom Dara Torres dives into a very important conversation this summer as she teams up with Celgene Corporation (NASDAQ:CELG) and...

What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio

What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio

Earlier this month the two major pharmacy benefit managers, CVS Caremark CVS and Express Scripts ESRX released lists of drugs they will no longer cover in 2017.

Should Gilead Split in Two?

Should Gilead Split in Two?

RBC Capital analysts say this would free 'trapped value' on drug treatments.

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

3 Biotech-Investing Mistakes to Avoid

3 Biotech-Investing Mistakes to Avoid

These are the biggest errors that I've made over the years.

CMCSA, IDXX, ZTS: Jim Cramer's Views

CMCSA, IDXX, ZTS: Jim Cramer's Views

Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.

Celgene Takes Over #29 Spot From Honeywell International

Celgene Takes Over #29 Spot From Honeywell International

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Celgene Corp. has taken over the #29 spot from Honeywell International Inc , according to ETF Channel.